A single-nucleotide polymorphism in the gene encoding osteoprotegerin is associated with diastolic blood pressure in older men

American Journal of Hypertension

Volumn 22, Issue 11, 2009, Pages 1167-1170

  Golledge, Jonathan ^a   Biros, Erik ^a   Clancy, Paula ^a   Cooper, Matthew ^b   Palmer, Lyle J ^b   Norman, Paul E ^b  

^a JAMES COOK UNIVERSITY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPROTEGERIN;

AGED; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC BLOOD PRESSURE;

AGED; AGED, 80 AND OVER; BLOOD PRESSURE; CHOLESTEROL; CREATINE; DNA FINGERPRINTING; HUMANS; HYPERTENSION; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; OSTEOPROTEGERIN; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 70350567730     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2009.177     Document Type: Article

References (19)

1. Van Campenhout A, Golledge J. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 2009; 204:321-329.
2. Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, Santer P, Smolen J, Poewe W, Willeit J. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004; 109:2175-2180.
3. Ueland T, Yndestad A, Øie E, Florholmen G, Halvorsen B, Frøland SS, Simonsen S, Christensen G, Gullestad L, Aukrust P. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation 2005; 111:2461-2468.
4. Golledge J, McCann M, Mangan S, Lam A, Karan M. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke 2004; 35:1636-1641.
5. Moran CS, McCann M, Karan M, Norman P, Ketheesan N, Golledge J. Association of osteoprotegerin with human abdominal aortic aneurysm progression. Circulation 2005; 111:3119-3125.
6. Omland T, Drazner MH, Ueland T, Abedin M, Murphy SA, Aukrust P, de Lemos JA. Plasma osteoprotegerin levels in the general population: relation to indices of left ventricular structure and function. Hypertension 2007; 49:1392-1398.
7. Bennett BJ, Scatena M, Kirk EA, Rattazzi M, Varon RM, Averill M, Schwartz SM, Giachelli CM, Rosenfeld ME. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/-mice. Arterioscler Thromb Vasc Biol 2006; 26:2117-2124.
8. Morony S, Tintut Y, Zhang Z, Cattley RC, Van G, Dwyer D, Stolina M, Kostenuik PJ, Demer LL. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Circulation 2008; 117:411-420.
9. Brändström H, Stiger F, Lind L, Kahan T, Melhus H, Kindmark A. A single nucleotide polymorphism in the promoter region of the human gene for osteoprotegerin is related to vascular morphology and function. Biochem Biophys Res Commun 2002; 293:13-17.
10. Brändström H, Stiger F, Kahan T, Melhus H, Nyström F, öHman K P, Malmqvist K, Lind L, Kindmark A. A single nucleotide polymorphism in the promoter region of the osteoprotegerin gene is related to intima-media thickness of the carotid artery in hypertensive patients. The Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA). Blood Press 2004; 13:152-157.
11. Golledge J, Clancy P, Jamrozik K, Norman PE. Obesity, adipokines, and abdominal aortic aneurysm: Health in Men study. Circulation 2007; 116:2275-2279.
12. Golledge J, Norman PE. Relationship between two sequence variations in the gene for peroxisome proliferator-activated receptor-gamma and plasma homocysteine concentration. Health in men study. Hum Genet 2008; 123:35-40.
13. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21:263-265.
14. Moran CS, Clancy P, Biros E, Blanco-Martin B, McCaskie P, Palmer LJ, Coomans D, Norman PE, Golledge J. Association of PPARgamma Allelic Variation, osteoprotegerin and abdominal aortic aneurysm. Clin Endocrinol (Oxf), in press.
15. Clancy P, Oliver L, Jayalath R, Buttner P, Golledge J. Assessment of a serum assay for quantification of abdominal aortic calcification. Arterioscler Thromb Vasc Biol 2006; 26:2574-2576.
16. Guo SW, Thompson EA. Performing the exact test of Hardy-Weinberg proportion for multiple alleles. Biometrics 1992; 42:361-372.
17. Mangiafico RA, Alagona C, Pennisi P, Parisi N, Mangiafico M, Purrello F, Fiore CE. Increased augmentation index and central aortic blood pressure in osteoporotic postmenopausal women. Osteoporos Int 2008; 19:49-56.
18. Rasmussen LM, Tarnow L, Hansen TK, Parving HH, Flyvbjerg A. Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol 2006; 154:75-81.
19. Uemura H, Yasui T, Miyatani Y, Yamada M, Hiyoshi M, Arisawa K, Irahara M. Circulating osteoprotegerin is associated with age and systolic blood pressure, but not with lipid profile or fasting glucose, in postmenopausal women. Menopause 2008; 15:180-184.